Among 5 ICC patients with high PD1+ T cells (>19 cells/200×), 4 patients had evident tumor progression, and 1 patient presented stable disease after three cycles of anti-PD1 immunotherapy (Figure 4A and B). Here, PDCD1 is linked to intrahepatic cholangiocarcinoma.